Episode 76
Targeting the Tumor Microenvironment in HCC
with Dr. Terence Gade and Dr. Michael Barraza
Interventional Radiologist Terence Gade from Penn Medicine, University of Pennsylvania Health System tells us about emerging research and therapies targeting the tumor microenvironment in Hepatocellular carcinoma (HCC).
Special thanks to our sponsor
BackTable, LLC (Producer). (2020, August 10). Ep. 76 – Targeting the Tumor Microenvironment in HCC [Audio podcast]. Retrieved from
In this Episode
Podcast Participants
Dr. Terence Gade is a practicing interventional radiologist with at the University of Pennsylvania.
Host Dr. Michael Barraza is a practicing interventional radiologist with Radiology Alliance in Nashville.
---
TriSalus Infusion Systems
TriSalus Life Sciences is dedicated to improving patient outcomes in HCC and other highly intractable solid tumors. TriSalus Infusion Systems have the potential to deliver diagnostic, therapeutic, and immuno-stimulant agents directly into the tumor vascular, powered by their proprietary pressure-enabled delivery approach.
Show Notes
Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy:
Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study:
Disclaimer: The Materials available on the BackTable Podcast are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Submit this form to get in touch with a rep and learn more about treating solid tumors with TriSalus Infusion Systems.
